Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 227-232

  Olmos, J M ^a   Zarrabeitia, M T ^a   Hernandez J L ^a   Saudo C ^a   Gonzalez Macias J ^a   Riancho, J A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

alendronate; bone mineral density; osteoclasts; osteoporosis; raloxifene; risedronate

Indexed keywords

ALENDRONIC ACID; GERANYLTRANSFERASE; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; DRUG RESPONSE; FDPS GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; GENE FREQUENCY; GERANYLTRANSTRANSFERASE; HAPLOTYPES; HUMANS; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; OSTEOPOROSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861456554     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.88     Document Type: Article

References (30)

1. Melton LJ. How many women have osteoporosis now? J Bone Miner Res 1995; 10: 175-177.
2. Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th edn. Lippincott Williams & Wilkins: Philadelphia, 2006.
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-645. (Pubitemid 29384151)
4. Kanis JA, Johnell O, Black DM, Downs Jr RW, Sarkar S, Fuerst T et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003; 33: 293-300. (Pubitemid 37107463)
5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541. (Pubitemid 26411651)
6. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Jonhston CC, Adami S et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 1997; 277: 1159-1164. (Pubitemid 27157636)
7. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1-12. (Pubitemid 30136655)
8. Brown JP, Kendler DL, McClung M, Emkey RD, Adachi JD, Bolognese MA et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-111. (Pubitemid 36935474)
9. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000; 85: 1895-1900. (Pubitemid 32269295)
10. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-1680.
11. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307-312. (Pubitemid 43670914)
12. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-759.
13. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005; 26: 6941-6949. (Pubitemid 41095518)
14. Riancho JA, Zarrabeitia MT, Gonzalez-Macias J. Genetics of osteoporosis. Aging Health 2008; 4: 365-376.
15. Richards JB, Kavvoura FK, Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 2009; 151: 528-537.
16. Gennari L. Pharmacogenomics of osteoporosis. Clin Rev Bone Miner Metab 2010; 8: 77-94.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
18. Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006; 34: W621-W625. (Pubitemid 44529845)
19. Reumers J, Conde L, Medina I, Maurer-Stroh S, Van Durme J, Dopazo J et al. Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeffect and PupaSuite databases. Nucleic Acids Res 2008; 36: D825-D829. (Pubitemid 351149830)
20. Emaus N, Berntsen GK, Joakimsen RM, Fonnebo V. Longitudinal changes in forearm bone mineral density in women and men aged 25-44 years: the Tromso study: a population-based study. Am J Epidemiol 2005; 162: 633-643. (Pubitemid 41437362)
21. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19: 1430-1438.
22. Ralston SH. Osteoporosis as an hereditary disease. Clin Rev Bone Miner Metab 2010; 8: 68-76.
23. Hernandez JL, Riancho JA. Pharmacogenomics of osteoporosis. Curr Pharmacogenom 2007; 5: 214-227. (Pubitemid 47455671)
24. Kruk M, Ralston SH, Albagha OM. LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 2009; 84: 171-179.
25. Levy ME, Parker RA, Ferrell RE, Zmuda JM, Greenspan SL. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007; 57: 247-252. (Pubitemid 46891698)
26. Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A et al. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term aminobisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 2008; 24: 2609-2615.
27. Choi HJ, Choi JY, Cho SW, Kang D, Han KO, Kim SW et al. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J 2010; 51: 231-238.
28. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239-244.
29. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005; 80: 379-388. (Pubitemid 40316301)
30. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, Lacroix AZ et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-289. (Pubitemid 34219441)